Expert founded and became CEO of EnzymeRx in order to gain practical operational experience in drug development, and was intimately involved in every aspect of the development of pegadricase for gout and tumor lysis syndrome. He directed IND-enabling preclinical studies, oversaw scale-up transfer of the manufacturing process to a contract manufacturer, wrote several phase 1 and 2 clinical trial protocols and two INDs, let all regulatory interactions with the FDA including pre-IND and type C meetings, and was the study director on two phase 1 trials.

These experiences give Expert a unique perspective on drug development and companies developing drugs. He is particularly skilled at assessing drug candidates, understanding end-markets and developing target product profiles and the clinical development program needed to attain that profile, strategically planning a translational program, and understanding what investors and partners want and expect to see in evaluating a company or drug candidates.

Have held series 7 and 63 and medical license (none active).

Has served on the board of Stemline, a private biotechnology company, and the boards of several not-for-profit institutions.

Expert has sourced preclinical and clinical CROs for GLP toxicology studies and clinical trials; he has also sourced contract manufacturers for development and production of a biologic.

He has had substantial experience analyzing intellectual property in an effort to assess patent robustness and potential infringement, and have drafted several patent applications. I have published 20 papers in the scientific and medical literature, presented data at national medical conferences, and designed corporate presentations and electronic data rooms.